Giampaolo Merlini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1283373/publications.pdf

Version: 2024-02-01

710 papers	52,527 citations	1370 108 h-index	1899 208 g-index
747 all docs	747 docs citations	747 times ranked	24830 citing authors

#	Article	IF	Citations
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology, The, 2014, 15, e538-e548.	5.1	3,343
2	International uniform response criteria for multiple myeloma. Leukemia, 2006, 20, 1467-1473.	3.3	2,332
3	Molecular Mechanisms of Amyloidosis. New England Journal of Medicine, 2003, 349, 583-596.	13.9	1,629
4	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. New England Journal of Medicine, 2018, 379, 1007-1016.	13.9	1,558
5	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
6	Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology, 2005, 79, 319-328.	2.0	1,179
7	Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 2018, 379, 22-31.	13.9	1,000
8	New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes. Journal of Clinical Oncology, 2012, 30, 4541-4549.	0.8	735
9	International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia, 2009, 23, 215-224.	3.3	686
10	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia, 2010, 24, 1121-1127.	3.3	677
11	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012, 26, 149-157.	3.3	664
12	Systemic Cardiac Amyloidoses. Circulation, 2009, 120, 1203-1212.	1.6	622
13	Repurposing Diflunisal for Familial Amyloid Polyneuropathy. JAMA - Journal of the American Medical Association, 2013, 310, 2658.	3.8	551
14	IMWG consensus on risk stratification in multiple myeloma. Leukemia, 2014, 28, 269-277.	3.3	500
15	Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 209-213.	1.4	473
16	Serum N-Terminal Proâ€“Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis. Circulation, 2003, 107, 2440-2445.	1.6	456
17	Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 221-224.	1.4	441
18	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	1.0	434

#	Article	IF	Citations
19	Amyloidosis: Pathogenesis and New Therapeutic Options. Journal of Clinical Oncology, 2011, 29, 1924-1933.	0.8	430
20	Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 215-219.	1.4	417
21	Dangerous small B-cell clones. Blood, 2006, 108, 2520-2530.	0.6	398
22	A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood, 2013, 121, 3420-3427.	0.6	385
23	Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood, 2004, 103, 2936-2938.	0.6	375
24	International prognostic scoring system for WaldenstrÃ¶m macroglobulinemia. Blood, 2009, 113, 4163-4170.	0.6	366
25	A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood, 2014, 124, 2325-2332.	0.6	366
26	Systemic immunoglobulin light chain amyloidosis. Nature Reviews Disease Primers, 2018, 4, 38.	18.1	350
27	Diagnosis, Prognosis, and Therapy ofÂTransthyretin Amyloidosis. Journal of the American College of Cardiology, 2015, 66, 2451-2466.	1.2	344
28	Diagnosis of monoclonal gammopathy of renal significance. Kidney International, 2015, 87, 698-711.	2.6	339
29	A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood, 2015, 126, 612-615.	0.6	334
30	Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia, 2012, 26, 2317-2325.	3.3	332
31	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, 2019, 15, 45-59.	4.1	330
32	Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation, 2019, 139, 431-443.	1.6	319
33	Amyloid: Toward terminology clarification Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 1-4.	1.4	314
34	Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation: Heart Failure, 2019, 12, e006075.	1.6	312
35	International Myeloma Working Group Recommendations for the Treatment of Multiple Myelomaâ€“Related Bone Disease. Journal of Clinical Oncology, 2013, 31, 2347-2357.	0.8	307
36	A primer of amyloid nomenclature. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 179-183.	1.4	306

#	Article	IF	Citations
37	Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 116-120.	0.8	304
38	Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2010, 17, 101-104.	1.4	302
39	Persistent efficacy of anakinra in patients with tumor necrosis factor receptorâ€“associated periodic syndrome. Arthritis and Rheumatism, 2008, 58, 1516-1520.	6.7	297
40	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia, 2013, 27, 780-791.	3.3	294
41	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. Journal of Clinical Oncology, 2016, 34, 1544-1557.	0.8	294
42	Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis. Journal of Clinical Oncology, 2010, 28, 1031-1037.	0.8	273
43	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. New England Journal of Medicine, 2021, 385, 46-58.	13.9	268
44	Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood, 2006, 107, 3854-3858.	0.6	266
45	Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 217-222.	1.4	265
46	Removal of the Nâ€terminal hexapeptide from human Î²2â€microglobulin facilitates protein aggregation and fibril formation. Protein Science, 2000, 9, 831-845.	3.1	263
47	Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis. Kidney International, 1998, 54, 650-671.	2.6	255
48	Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. European Heart Journal, 2013, 34, 520-528.	1.0	252
49	Eprodisate for the Treatment of Renal Disease in AA Amyloidosis. New England Journal of Medicine, 2007, 356, 2349-2360.	13.9	240
50	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	1.4	230
51	Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 167-170.	1.4	229
52	Response assessment in <scp>W</scp>aldenstrÃ¶m macroglobulinaemia: update from the <scp>VI</scp>th <scp>I</scp>nternational <scp>W</scp>orkshop. British Journal of Haematology, 2013, 160, 171-176.	1.2	226
53	Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine. Clinical Chemistry, 2009, 55, 499-504.	1.5	225
54	Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia, 2012, 26, 595-608.	3.3	217

#	Article	IF	Citations
55	Clinical aspects of systemic amyloid diseases. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1753, 11-22.	1.1	215
56	Systemic light chain amyloidosis: an update for treating physicians. Blood, 2013, 121, 5124-5130.	0.6	214
57	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia, 2014, 28, 525-542.	3.3	214
58	The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood, 2005, 105, 2949-2951.	0.6	207
59	Update on Treatment Recommendations From the Fourth International Workshop on WaldenstrÃ¶m's Macroglobulinemia. Journal of Clinical Oncology, 2009, 27, 120-126.	0.8	207
60	International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia, 2009, 23, 1904-1912.	3.3	207
61	Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 2959-2963.	3.3	198
62	The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. Journal of Internal Medicine, 2004, 255, 159-178.	2.7	198
63	Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Advances in Therapy, 2015, 32, 920-928.	1.3	187
64	The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood, 2010, 116, 3426-3430.	0.6	184
65	Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 34-36.	1.4	184
66	What is new in diagnosis and management of light chain amyloidosis?. Blood, 2016, 128, 159-168.	0.6	184
67	WaldenstrÃ¶m macroglobulinemia. Blood, 2007, 109, 5096-5103.	0.6	183
68	Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood, 2007, 110, 787-788.	0.6	182
69	Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. Journal of Hematology and Oncology, 2018, 11, 10.	6.9	181
70	Primary therapy of WaldenstrÃ¶m macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood, 2013, 122, 3276-3282.	0.6	180
71	Review: Immunoglobulin Light Chain Amyloidosisâ€"The Archetype of Structural and Pathogenic Variability. Journal of Structural Biology, 2000, 130, 280-289.	1.3	179
72	Biomarkers of Acute Kidney Injury. Advances in Chronic Kidney Disease, 2008, 15, 222-234.	0.6	177

#	Article	IF	Citations
73	Amyloid Fibril Protein Nomenclature - 2002. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 197-200.	1.4	176
74	First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of Clinical Oncology, 2016, 34, 1097-1103.	0.8	176
75	Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood, 2018, 132, 1478-1485.	0.6	173
76	Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood, 2011, 118, 865-873.	0.6	161
77	Treatment recommendations from the Eighth International Workshop on WaldenstrÃ¶mâ€™s Macroglobulinemia. Blood, 2016, 128, 1321-1328.	0.6	161
78	A practical approach to the diagnosis of systemic amyloidoses. Blood, 2015, 125, 2239-2244.	0.6	156
79	Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood, 2012, 119, 1844-1847.	0.6	155
80	Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): IFCC Scientific Division Committee on Plasma Proteins (C-PP). Clinical Chemistry and Laboratory Medicine, 2007, 45, 419-26.	1.4	154
81	Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood, 2009, 114, 1489-1497.	0.6	153
82	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp>orking <scp>G</scp>roup on <scp>M</scp>yocardial and <scp>P</scp>ericardial <scp>D</scp>iseases. European Journal of Heart Failure, 2021, 23, 512-526.	2.9	153
83	Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. Journal of Translational Medicine, 2010, 8, 74.	1.8	149
84	Analysis of VÎ»-JÎ» expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r(Î»III) as a new amyloid-associated germline gene segment. Blood, 2002, 100, 948-953.	0.6	147
85	Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood, 2020, 136, 71-80.	0.6	146
86	Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 108-114.	1.4	141
87	Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. Journal of Neurology, 2021, 268, 2109-2122.	1.8	141
88	Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica, 2014, 99, 743-750.	1.7	138
89	Treatment recommendations for patients with WaldenstrÃ¶m macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood, 2014, 124, 1404-1411.	0.6	138
90	A Partially Structured Species of Î²2-Microglobulin Is Significantly Populated under Physiological Conditions and Involved in Fibrillogenesis. Journal of Biological Chemistry, 2001, 276, 46714-46721.	1.6	137

#	Article	IF	Citations
91	AL amyloidosis: from molecular mechanisms to targeted therapies. Hematology American Society of Hematology Education Program, 2017, 2017, 1-12.	0.9	137
92	Amyloidogenic and Associated Proteins in Systemic Amyloidosis Proteome of Adipose Tissue. Molecular and Cellular Proteomics, 2008, 7, 1570-1583.	2.5	134
93	Management of AL amyloidosis in 2020. Blood, 2020, 136, 2620-2627.	0.6	133
94	Outrageous prices of orphan drugs: a call for collaboration. Lancet, The, 2018, 392, 791-794.	6.3	132
95	New drug therapy of amyloidoses: resorption of AL-type deposits with 4'- iodo-4'-deoxydoxorubicin. Blood, 1995, 86, 855-861.	0.6	128
96	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer Journal, 2020, 10, 102.	2.8	126
97	Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2006, 13, 191-205.	1.4	124
98	Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurology and Therapy, 2016, 5, 1-25.	1.4	124
99	A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood, 1980, 55, 1011-1019.	0.6	123
100	Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 305, H95-H103.	1.5	123
101	Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis. Journal of Cardiovascular Translational Research, 2013, 6, 1011-1020.	1.1	122
102	A Caenorhabditis elegansâ€“based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood, 2014, 123, 3543-3552.	0.6	122
103	The lung in amyloidosis. European Respiratory Review, 2017, 26, 170046.	3.0	122
104	Treatment of cardiac transthyretin amyloidosis: an update. European Heart Journal, 2019, 40, 3699-3706.	1.0	121
105	Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood, 1994, 83, 2939-2945.	0.6	117
106	4 â€²â€iodoâ€4â€²â€Ðeoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB Journal, 2003, 17, 803-809.	0.2	117
107	Holter Monitoring in AL Amyloidosis: Prognostic Implications. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 1228-1233.	0.5	115
108	Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched caseâ€“control study on 174 patients. Leukemia, 2014, 28, 2311-2316.	3.3	113

#	Article	IF	Citations
109	Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient. Nature Communications, 2019, 10, 1269.	5.8	113
110	Rapid progression of familial amyloidotic polyneuropathy. Neurology, 2015, 85, 675-682.	1.5	109
111	The New Apolipoprotein A-I Variant Leu174 â†' Ser Causes Hereditary Cardiac Amyloidosis, and the Amyloid Fibrils Are Constituted by the 93-Residue N-Terminal Polypeptide. American Journal of Pathology, 1999, 155, 695-702.	1.9	108
112	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood, 2017, 130, 597-605.	0.6	108
113	Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood, 2017, 130, 625-631.	0.6	108
114	beta 2-microglobulin can be refolded into a native state from ex vivo amyloid fibrils. FEBS Journal, 1998, 258, 61-67.	0.2	107
115	Update on Recommendations for Assessing Response from the Third International Workshop on WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2006, 6, 380-383.	1.4	107
116	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	0.7	107
117	Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 142-150.	1.4	106
118	Efficacy and safety of tafamidis doses in the <scp>Tafamidis in Transthyretin Cardiomyopathy Clinical Trial</scp> (<scp>ATTRâ€ACT</scp>) and longâ€term extension study. European Journal of Heart Failure, 2021, 23, 277-285.	2.9	103
119	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. Journal of Clinical Oncology, 2020, 38, 3252-3260.	0.8	102
120	Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. Arthritis and Rheumatism, 2009, 61, 1435-1440.	6.7	100
121	Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Seminars in Oncology, 2003, 30, 211-215.	0.8	99
122	The repertoire of Î» light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood, 2012, 119, 144-150.	0.6	98
123	Immunoglobulin light chain amyloidosis. Expert Review of Hematology, 2014, 7, 143-156.	1.0	98
124	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€"Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	1.4	97
125	Amyloidosis in autoinflammatory syndromes. Autoimmunity Reviews, 2012, 12, 14-17.	2.5	96
126	Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. American Journal of Hematology, 2012, 87, 465-471.	2.0	95

#	Article	IF	Citations
127	A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood, 2020, 135, 1531-1540.	0.6	94
128	The utility of MASSâ€FIX to detect and monitor monoclonal proteins in the clinic. American Journal of Hematology, 2017, 92, 772-779.	2.0	93
129	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurology, The, 2021, 20, 49-59.	4.9	93
130	AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Medical Weekly, 2012, 142, w13580.	0.8	87
131	Conformational Switching and Fibrillogenesis in the Amyloidogenic Fragment of Apolipoprotein A-I. Journal of Biological Chemistry, 2003, 278, 2444-2451.	1.6	86
132	Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Annals of the Rheumatic Diseases, 2011, 70, 1511-1512.	0.5	86
133	Bortezomib in the treatment of AL amyloidosis: targeted therapy?. Haematologica, 2007, 92, 1302-1307.	1.7	85
134	Saporin, a ribosomeâ€inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. British Journal of Haematology, 1996, 93, 789-794.	1.2	84
135	Pharmacokinetic Behavior of Rituximab. Therapeutic Drug Monitoring, 2005, 27, 785-792.	1.0	84
136	Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 1393-1401.	2.2	83
137	Renal Apolipoprotein A-I Amyloidosis: A Rare and Usually Ignored Cause of Hereditary Tubulointerstitial Nephritis. Journal of the American Society of Nephrology: JASN, 2005, 16, 3680-3686.	3.0	83
138	Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 40-48.	1.4	83
139	Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 457-458.	0.9	83
140	The Controlling Roles of Trp60 and Trp95 in Î²2-Microglobulin Function, Folding and Amyloid Aggregation Properties. Journal of Molecular Biology, 2008, 378, 887-897.	2.0	82
141	A novelAÎ²PP mutation exclusively associated with cerebral amyloid angiopathy. Annals of Neurology, 2005, 58, 639-644.	2.8	81
142	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia, 2018, 32, 1883-1898.	3.3	81
143	Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology American Society of Hematology Education Program, 2012, 2012, 595-603.	0.9	80
144	Light chain amyloidosis: the heart of the problem. Haematologica, 2013, 98, 1492-1495.	1.7	80

#	Article	IF	Citations
145	First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis and Rheumatism, 2004, 50, 2966-2969.	6.7	79
146	Amyloidosis and Waldenstroì^mâ€™s Macroglobulinemia. Hematology American Society of Hematology Education Program, 2004, 2004, 257-282.	0.9	78
147	Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Annals of Hematology, 2012, 91, 89-92.	0.8	78
148	A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood, 2017, 129, 2120-2123.	0.6	76
149	Diagnostic and Prognostic Value of Low QRS Voltages in Cardiac AL Amyloidosis. Annals of Noninvasive Electrocardiology, 2013, 18, 271-280.	0.5	75
150	Lysozyme: A paradigmatic molecule for the investigation of protein structure, function and misfolding. Clinica Chimica Acta, 2005, 357, 168-172.	0.5	74
151	Immunoglobulin M Monoclonal Gammopathies of Undetermined Significance and Indolent WaldenstrÃ¶m's Macroglobulinemia Recognize the Same Determinants of Evolution Into Symptomatic Lymphoid Disorders: Proposal for a Common Prognostic Scoring System. Journal of Clinical Oncology, 2005, 23, 4662-4668.	0.8	73
152	Multiple myeloma. Annals of Oncology, 2010, 21, vii143-vii150.	0.6	73
153	Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia, 2016, 30, 1979-1986.	3.3	73
154	The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: Clinical manifestations and long-term follow-up. Seminars in Arthritis and Rheumatism, 2014, 43, 818-823.	1.6	71
155	Nâ€terminal fragment of the typeâ€B natriuretic peptide (NTâ€proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2016, 91, 1129-1134.	2.0	71
156	Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology, 2004, 126, 1416-1422.	0.6	70
157	The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. Blood, 2017, 129, 2132-2142.	0.6	70
158	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€”Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	0.7	70
159	LONG-TERM EFFECTS OF PARENTERAL DICHLOROMETHYLENE BISPHOSPHONATE (CL2MBP) ON BONE DISEASE OF MYELOMA PATIENTS TREATED WITH CHEMOTHERAPY. Hematological Oncology, 1990, 8, 23-30.	0.8	69
160	Variable presentations of TTRâ€related familial amyloid polyneuropathy in seventeen patients. Journal of the Peripheral Nervous System, 2011, 16, 119-129.	1.4	68
161	Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis. JAMA Cardiology, 2019, 4, 466.	3.0	68
162	Neuropathies associated with monoclonal gammopathies. Neuromuscular Disorders, 1996, 6, 3-18.	0.3	67

#	Article	IF	Citations
163	A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. British Journal of Haematology, 2001, 113, 1044-1046.	1.2	67
164	Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Annals of Hematology, 2009, 88, 347-350.	0.8	67
165	Characterization of the New Serum Protein Reference Material ERM-DA470k/IFCC: Value Assignment by Immunoassay. Clinical Chemistry, 2010, 56, 1880-1888.	1.5	67
166	Expert review on softâ€tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. British Journal of Haematology, 2021, 194, 496-507.	1.2	67
167	Monoclonal immunoglobulins with antibody activity in myeloma, macroglobulinemia and related plasma cell dyscrasias. Seminars in Oncology, 1986, 13, 350-65.	0.8	66
168	Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. British Journal of Haematology, 1990, 74, 65-69.	1.2	65
169	A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica, 2013, 98, 433-436.	1.7	65
170	Amyloidosis: is a cure possible?. Annals of Oncology, 2008, 19, iv63-iv66.	0.6	64
171	In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study. Scientific Reports, 2016, 6, 29096.	1.6	63
172	Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. Scientific Reports, 2017, 7, 15661.	1.6	63
173	The workings of the amyloid diseases. Annals of Medicine, 2007, 39, 200-207.	1.5	62
174	Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood, 2014, 124, 2498-2506.	0.6	62
175	BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood, 2017, 129, 456-459.	0.6	62
176	Light chain amyloidosis. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 10, e2018022.	0.5	62
177	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer Journal, 2021, 11, 192.	2.8	62
178	Prognostic Validation of the International Classification of Immunoglobulin M Gammopathies: A Survival Advantage for Patients with Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance?. Clinical Cancer Research, 2005, 11, 1786-1790.	3.2	61
179	Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. European Journal of Heart Failure, 2007, 9, 808-813.	2.9	61
180	SjÃ¶gren's syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity?. Arthritis and Rheumatism, 2008, 58, 1992-1999.	6.7	61

#	Article	IF	Citations
181	Recommendations for the diagnosis and initial evaluation of patients with WaldenstrÃ¶m Macroglobulinaemia: A Task Force from the 8th International Workshop on WaldenstrÃ¶m Macroglobulinaemia. British Journal of Haematology, 2016, 175, 77-86.	1.2	61
182	Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. FASEB Journal, 2015, 29, 4614-4628.	0.2	60
183	European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin Mâ€"Related Light Chain Amyloidosis. Journal of Clinical Oncology, 2016, 34, 2037-2045.	0.8	60
184	Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 2020, 21, 198.	2.9	60
185	The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 80-82.	1.4	59
186	Impaired Osteoblastogenesis in a Murine Model of Dominant Osteogenesis Imperfecta: A New Target for Osteogenesis Imperfecta Pharmacological Therapy. Stem Cells, 2012, 30, 1465-1476.	1.4	59
187	Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy) Tj ETQq1 1 0.784314 rgBT /Ov	1.6	59
188	Light and electron microscopy immunohistochemical characterization of amyloid deposits. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1997, 4, 157-170.	1.4	58
189	Autoantibody Activity in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2005, 5, 225-229.	2.1	58
190	Investigation and management of IgM and WaldenstrÃ¶mâ€associated peripheral neuropathies: recommendations from the <scp>IWWM</scp>â€8 consensus panel. British Journal of Haematology, 2017, 176, 728-742.	1.2	58
191	Study of three patients with monoclonal gammopathies and â€˜lupus-likeâ€™ anticoagulants. British Journal of Haematology, 1989, 73, 221-227.	1.2	57
192	Novel Type of Renal Amyloidosis Derived from Apolipoprotein-CII. Journal of the American Society of Nephrology: JASN, 2017, 28, 439-445.	3.0	57
193	Evidence That Amyloidogenic Light Chains Undergo Antigen-Driven Selection. Blood, 1998, 91, 2948-2954.	0.6	56
194	Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?. Rheumatology, 2005, 44, 1074-1075.	0.9	56
195	Â2-Microglobulin isoforms display an heterogeneous affinity for type I collagen. Protein Science, 2005, 14, 696-702.	3.1	56
196	Current treatment of AL amyloidosis. Haematologica, 2009, 94, 1044-1048.	1.7	56
197	Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Research in Cardiology, 2013, 108, 378.	2.5	56
198	4â€²-Iodo-4â€²-Deoxydoxorubicin Disrupts the Fibrillar Structure of Transthyretin Amyloid. American Journal of Pathology, 2000, 156, 1919-1925.	1.9	55

#	Article	IF	Citations
199	Lenalidomide and dexamethasone in patients with <scp>POEMS</scp> syndrome: results of a prospective, openâ€label trial. British Journal of Haematology, 2017, 179, 748-755.	1.2	55
200	Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 143-155.	1.4	55
201	A multicenter phase II trial of 4â€²-iodo-4â€²-deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 24-30.	1.4	54
202	Redefining myeloma. Nature Reviews Clinical Oncology, 2012, 9, 494-496.	12.5	54
203	Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis. American Journal of Clinical Nutrition, 2006, 83, 350-354.	2.2	53
204	Topological investigation of amyloid fibrils obtained from Î²2-microglobulin. Protein Science, 2009, 11, 2362-2369.	3.1	53
205	Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients. Leukemia, 2019, 33, 254-257.	3.3	53
206	A revised international prognostic score system for WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia, 2019, 33, 2654-2661.	3.3	53
207	Biological Variation of N-Terminal Pro-Brain Natriuretic Peptide in Healthy Individuals. Clinical Chemistry, 2003, 49, 1554-1555.	1.5	52
208	Coverage and yield of entry and follow-up screening for tuberculosis among new immigrants. European Respiratory Journal, 2008, 32, 153-161.	3.1	52
209	CyBorD: stellar response rates in AL amyloidosis. Blood, 2012, 119, 4343-4345.	0.6	52
210	Stabilization of amyloidogenic immunoglobulin light chains by small molecules. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8360-8369.	3.3	52
211	Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood, 2018, 131, 525-532.	0.6	51
212	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e006588.	1.3	51
213	ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 259-265.	1.4	51
214	Cardiac immunocyte-derived (AL) amyloidosis: An endomyocardial biopsy study in 11 patients. American Heart Journal, 1995, 130, 528-536.	1.2	50
215	Prognostic Role of Clinical and Laboratory Criteria To Identify Early Ventilator-Associated Pneumonia in Brain Injury*. Chest, 2008, 134, 101-108.	0.4	50
216	Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity. Scientific Reports, 2017, 7, 16809.	1.6	50

#	Article	IF	Citations
217	Systemic amyloidosis: novel therapies and role of biomarkers. Nephrology Dialysis Transplantation, 2017, 32, gfw305.	0.4	49
218	Early data on longâ€term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2â€year update from the openâ€label extension of the NEUROâ€TTR trial. European Journal of Neurology, 2020, 27, 1374-1381.	1.7	49
219	Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 1-2.	1.4	49
220	BIOLOGY AND THERAPY OF IMMUNOGLOBULIN DEPOSITION DISEASES. Hematology/Oncology Clinics of North America, 1997, 11, 89-110.	0.9	48
221	Pharmaceutical Strategies Against Amyloidosis: Old and New Drugs in Targeting a “Protein Misfolding Disease”. Current Medicinal Chemistry, 2004, 11, 1065-1084.	1.2	48
222	Multicentre versus single centre approach to rare diseases: The model of systemic light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2005, 12, 120-126.	1.4	48
223	Effects of the Known Pathogenic Mutations on the Aggregation Pathway of the Amyloidogenic Peptide of Apolipoprotein A-I. Journal of Molecular Biology, 2011, 407, 465-476.	2.0	48
224	Prognostic value of fragmented QRS in cardiac AL amyloidosis. International Journal of Cardiology, 2013, 167, 2156-2161.	0.8	48
225	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	1.3	48
226	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica, 2004, 89, 717-41.	1.7	48
227	Acute phase proteins and prognosis in multiple myeloma. British Journal of Haematology, 1993, 83, 595-601.	1.2	47
228	Guidelines for the Analysis of Bence Jones Protein. Clinical Chemistry and Laboratory Medicine, 2003, 41, 338-46.	1.4	47
229	An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert Opinion on Investigational Drugs, 2014, 23, 1239-1251.	1.9	47
230	Treatment of primary amyloidosis. Seminars in Hematology, 1995, 32, 60-79.	1.8	47
231	Therapeutic advances demand accurate typing of amyloid deposits. American Journal of Medicine, 2001, 111, 243-244.	0.6	46
232	Rare diseases and effective treatments: are we delivering?. Lancet, The, 2015, 385, 750-752.	6.3	46
233	Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 701-708.	3.3	45
234	Occurrence of monoclonal components in general practice: Clinical implications. European Journal of Haematology, 1992, 48, 192-195.	1.1	45

#	Article	IF	Citations
235	AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity. Clinical Lymphoma and Myeloma, 2009, 9, 80-83.	1.4	45
236	Shotgun Protein Profile of Human Adipose Tissue and Its Changes in Relation to Systemic Amyloidoses. Journal of Proteome Research, 2013, 12, 5642-5655.	1.8	45
237	Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. Protein Science, 2001, 10, 187-199.	3.1	44
238	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Blood, 2018, 131, 1568-1575.	0.6	44
239	First Report of Circulating MicroRNAs in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS). PLoS ONE, 2013, 8, e73443.	1.1	44
240	TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients. Neurological Sciences, 2013, 34, 1057-1063.	0.9	43
241	The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-Î²B pathway. Arthritis Research and Therapy, 2015, 17, 93.	1.6	43
242	The molecular interaction of 4â€²-iodo-4â€²-deoxydoxorubicin with Leu-55Pro transthyretin â€˜amyloid-likeâ€™ oligomer leading to disaggregation. Biochemical Journal, 2000, 351, 273-279.	1.7	42
243	Assessing mNIS+7_{Ionis} and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial. Muscle and Nerve, 2017, 56, 901-911.	1.0	42
244	Treatment of AL Amyloidosis with 4â€²-Iodo-4â€²-Deoxydoxorubicin: An Update. Blood, 1999, 93, 1112-1113.	0.6	41
245	Serum amyloid A, procalcitonin, and C-reactive protein in early assessment of severity of acute pancreatitis. Digestive Diseases and Sciences, 2000, 45, 1072-1078.	1.1	41
246	Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 957-970.	0.2	40
247	Prevalence and Prognostic Value of Conduction Disturbances at the Time of Diagnosis of Cardiac AL Amyloidosis. Annals of Noninvasive Electrocardiology, 2013, 18, 327-335.	0.5	40
248	A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2011, 1814, 409-419.	1.1	39
249	The Diflunisal Trial: Study accrual and drug tolerance. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 37-38.	1.4	39
250	Human osteogenic differentiation in Space: proteomic and epigenetic clues to better understand osteoporosis. Scientific Reports, 2019, 9, 8343.	1.6	39
251	Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Blood Cancer Journal, 2021, 11, 34.	2.8	39
252	Is accuracy of serum free light chain measurement achievable?. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1021-30.	1.4	38

#	Article	IF	Citations
253	Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage. Antioxidants and Redox Signaling, 2017, 27, 567-582.	2.5	38
254	The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica, 1999, 84, 218-21.	1.7	38
255	Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension?. British Heart Journal, 2002, 88, 615-621.	2.2	37
256	Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis, 2007, 28, 2053-2064.	1.3	37
257	Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions. Expert Review of Molecular Diagnostics, 2014, 14, 55-66.	1.5	37
258	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. Blood, 2016, 128, 646-646.	0.6	37
259	Clotting alterations in primary systemic amyloidosis. Haematologica, 2000, 85, 289-92.	1.7	37
260	Proteomics of Î²2-microglobulin amyloid fibrils. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1753, 23-33.	1.1	36
261	Treatment of IgM-Associated AL Amyloidosis With the Combination of Rituximab, Bortezomib, and Dexamethasone. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 143-145.	0.2	36
262	Transplantation vs. conventional-dose therapy for amyloidosis. Current Opinion in Oncology, 2011, 23, 214-220.	1.1	36
263	A human myeloma immunoglobulin G binding four moles of calcium associated with asymptomatic hypercalcemia. Journal of Clinical Immunology, 1984, 4, 185-196.	2.0	35
264	Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. American Journal of Hematology, 1994, 46, 189-193.	2.0	35
265	Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 133-140.	1.4	35
266	Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis. Annals of Hematology, 2012, 91, 399-406.	0.8	35
267	Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology American Society of Hematology Education Program, 2012, 2012, 595-603.	0.9	35
268	Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 108-14.	1.4	35
269	Clinical Pregenetic Screening for Stroke Monogenic Diseases. Stroke, 2016, 47, 1702-1709.	1.0	34
270	MASSâ€FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms. American Journal of Hematology, 2018, 93, E368-E370.	2.0	34

#	Article	IF	Citations
271	Management of AL amyloidosis in 2020. Hematology American Society of Hematology Education Program, 2020, 2020, 363-371.	0.9	34
272	Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). Blood, 2019, 134, 139-139.	0.6	34
273	Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery. Metabolism: Clinical and Experimental, 1982, 31, 1100-1104.	1.5	33
274	Clinical proteomics for diagnosis and typing of systemic amyloidoses. Proteomics - Clinical Applications, 2013, 7, 136-143.	0.8	33
275	Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1734-1743.	1.4	33
276	Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica, 2006, 91, 1635-43.	1.7	33
277	Standardizing plasma protein measurements worldwide: a challenging enterprise. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1567-1575.	1.4	32
278	Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma. Leukemia, 2017, 31, 1735-1742.	3.3	32
279	Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis. Journal of Biological Chemistry, 2020, 295, 16572-16584.	1.6	32
280	The clinical implications of monoclonal immunoglobulins. Seminars in Oncology, 1986, 13, 366-79.	0.8	32
281	Translocation t(4;14)(p16.3;q32) Is a Recurrent Genetic Lesion in Primary Amyloidosis. American Journal of Pathology, 2001, 158, 1599-1603.	1.9	31
282	Systemic amyloidoses: What an internist should know. European Journal of Internal Medicine, 2013, 24, 729-739.	1.0	31
283	The red cell distribution width (RDW): Value and role in preterm, IUGR (intrauterine growth) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	0.7	31
284	Monitoring free light chains in serum using mass spectrometry. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1073-83.	1.4	31
285	Attitudes about when and how to treat patients with AL amyloidosis: an international survey. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 213-216.	1.4	31
286	Therapies for cardiac light chain amyloidosis: An update. International Journal of Cardiology, 2018, 271, 152-160.	0.8	31
287	Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 97-102.	1.4	31
288	How I treat AL amyloidosis. Blood, 2022, 139, 2918-2930.	0.6	31

#	Article	IF	Citations
289	Mechanism of Altered Drug Binding to Serum Proteins in Pregnant Women. Therapeutic Drug Monitoring, 1984, 6, 25-30.	1.0	30
290	Serum prealbumin: An independent marker of short-term energy intake in the presence of multiple-organ disease involvement. Nutrition, 2013, 29, 580-582.	1.1	30
291	Treatment of AL amyloidosis with bendamustine: a study of 122 patients. Blood, 2018, 132, 1988-1991.	0.6	30
292	Amino acid sequence of k Sci, the Bence Jones protein isolated from a patient with light chain deposition disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1991, 1097, 177-182.	1.8	29
293	Protein Aggregation. Clinical Chemistry and Laboratory Medicine, 2001, 39, 1065-75.	1.4	29
294	Novel strategies for the diagnosis and treatment of cardiac amyloidosis. Expert Review of Cardiovascular Therapy, 2015, 13, 1195-1211.	0.6	29
295	Monoclonal IgM-related AL amyloidosis. Best Practice and Research in Clinical Haematology, 2016, 29, 241-248.	0.7	29
296	High rate of profound clonal and renal responses with daratumumab treatment in heavily preâ€treated patients with <scp>light chain (AL)</scp> amyloidosis and high bone marrow plasma cell infiltrate. American Journal of Hematology, 2020, 95, 900-905.	2.0	29
297	A randomized phase 3 study of ixazomibâ€“dexamethasone versus physicianâ€™s choice in relapsed or refractory AL amyloidosis. Leukemia, 2022, 36, 225-235.	3.3	29
298	Use of Anti-(beta2 Microglobulin) mAb to Study Formation of Amyloid Fibrils. FEBS Journal, 1997, 249, 21-26.	0.2	28
299	Molecular and Functional Bases of Self-Antigen Recognition in Long-Term Persistent Melanocyte-Specific CD8+ T Cells in One Vitiligo Patient. Journal of Investigative Dermatology, 2003, 121, 308-314.	0.3	28
300	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. Annals of Hematology, 2012, 91, 875-888.	0.8	28
301	Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosis. Kidney International, 2015, 87, 1223-1229.	2.6	28
302	Therapy and management of systemic AL (primary) amyloidosis. Swiss Medical Weekly, 2006, 136, 715-20.	0.8	28
303	Serum Amyloid A and C-Reactive Protein Independently Predict the Recurrences of Atrial Fibrillation After Cardioversion in Patients With Preserved Left Ventricular Function. Canadian Journal of Cardiology, 2012, 28, 537-541.	0.8	27
304	Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis. Blood, 2020, 135, 293-296.	0.6	27
305	Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients. Blood, 2019, 134, 3166-3166.	0.6	27
306	Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. Blood Advances, 2020, 4, 1321-1324.	2.5	27

#	Article	IF	Citations
307	New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. Blood, 1995, 86, 855-61.	0.6	27
308	Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 216-221.	1.4	26
309	Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities. Nephrology Dialysis Transplantation, 2012, 27, 3713-3718.	0.4	26
310	Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis. Nutrition, 2015, 31, 1228-1234.	1.1	26
311	Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 10-14.	1.4	26
312	ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis. Analytical Chemistry, 2019, 91, 2894-2900.	3.2	26
313	Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains. Journal of Molecular Biology, 2020, 432, 845-860.	2.0	26
314	Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis. JACC: Heart Failure, 2021, 9, 736-746.	1.9	26
315	When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression. Blood Advances, 2019, 3, 212-215.	2.5	25
316	Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses. Frontiers in Pharmacology, 2020, 11, 1024.	1.6	25
317	Proteaseâ€sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation. FEBS Journal, 2022, 289, 494-506.	2.2	25
318	A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis. Blood, 2010, 116, 988-988.	0.6	25
319	Current concepts on the pathogenesis of systemic amyloidosis. Nephrology Dialysis Transplantation, 1996, 11, 53-62.	0.4	24
320	The molecular interaction of 4â€²-iodo-4â€²-deoxydoxorubicin with Leu-55Pro transthyretin â€˜amyloid-likeâ€™ oligomer leading to disaggregation. Biochemical Journal, 2000, 351, 273.	1.7	24
321	Lysine 58-cleaved beta2-microglobulin is not detectable by 2D electrophoresis in ex vivo amyloid fibrils of two patients affected by dialysis-related amyloidosis. Protein Science, 2006, 16, 343-349.	3.1	24
322	Infertility and Hypergonadotropic Hypogonadism as First Evidence of Hereditary Apolipoprotein A-I Amyloidosis. Journal of Urology, 2007, 178, 344-348.	0.2	24
323	Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 173-178.	1.4	24
324	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-Î± Receptorâ€”Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. Mediators of Inflammation, 2020, 2020, 1-12.	1.4	24

#	Article	IF	Citations
325	Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis. Blood Advances, 2020, 4, 4175-4179.	2.5	24
326	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. Blood Cancer Journal, 2020, 10, 41.	2.8	24
327	Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis. Cells, 2021, 10, 545.	1.8	24
328	Immunoglobulin Light Chain Systemic Amyloidosis. Cancer Treatment and Research, 2016, 169, 273-318.	0.2	23
329	Management of the elderly patient with AL amyloidosis. European Journal of Internal Medicine, 2018, 58, 48-56.	1.0	23
330	International Prognostic Scoring System (IPSS) for Waldenstroì^mâ€™s Macroglobulinemia (WM).. Blood, 2006, 108, 127-127.	0.6	23
331	Persistence of Minimal Residual Disease By Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients with AL Amyloidosis Otherwise in Complete Response. Blood, 2016, 128, 3261-3261.	0.6	23
332	Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). Biology of Blood and Marrow Transplantation, 2008, 14, 6-11.	2.0	22
333	The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: A possible impact on the natural history of the disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 87-93.	1.8	22
334	Diagnostic Performance of Triggering Receptor Expressed on Myeloid Cells-1 and CD64 Index as Markers of Sepsis in Preterm Newborns. Pediatric Critical Care Medicine, 2013, 14, 178-182.	0.2	22
335	Biochemical markers in early diagnosis and management of systemic amyloidoses. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1517-31.	1.4	22
336	Amyloidosis and Ocular Involvement: an Overview. Seminars in Ophthalmology, 2020, 35, 7-26.	0.8	22
337	Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer. BMJ Open, 2019, 9, e025483.	0.8	22
338	Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update. Orphanet Journal of Rare Diseases, 2022, 17, .	1.2	22
339	Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2023, 30, 3-17.	1.4	22
340	Inverse Polymerase Chain Reaction for Cloning Complete Human Immunoglobulin Variable Regions and Leaders Conserving the Original Sequence. Analytical Biochemistry, 1996, 239, 107-109.	1.1	21
341	Paraprotein Interference in an Assay of Conjugated Bilirubin. Clinical Chemistry, 2005, 51, 1076-1077.	1.5	21
342	A multi-fpga 10x-real-time high-speed search engine for a 5000-word vocabulary speech recognizer. , 2009, , .		21

#	Article	IF	Citations
343	Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 92-93.	1.4	21
344	WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2014, 28, 945-970.	0.9	21
345	Predicting survival in light chain amyloidosis. Haematologica, 2019, 104, 1294-1296.	1.7	21
346	Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib at the Recommended Phase 3 Dose (RP3D) in Patients (Pts) with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis (RRAL). Blood, 2014, 124, 3450-3450.	0.6	21
347	A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood, 1980, 55, 1011-9.	0.6	21
348	Detection and identification of monoclonal components: immunoelectrophoresis on agarose gel and immunofixation on cellulose acetate compared.. Clinical Chemistry, 1981, 27, 1862-1865.	1.5	20
349	The diflunisal trial: update on study drug tolerance and disease progression. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 196-197.	1.4	20
350	Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis. Journal of Hypertension, 2014, 32, 1121-1131.	0.3	20
351	Novel Therapies in Light Chain Amyloidosis. Kidney International Reports, 2018, 3, 530-541.	0.4	20
352	Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. Journal of Neurology, 2020, 267, 1070-1079.	1.8	20
353	Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 231-236.	1.4	20
354	A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E. coli. PLoS ONE, 2013, 8, e76022.	1.1	20
355	Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis. Bone Marrow Transplantation, 1999, 23, 323-327.	1.3	19
356	Hereditary Amyloidosis. New England Journal of Medicine, 2002, 347, 1206-1207.	13.9	19
357	Ultrastructural organization of ex vivo amyloid fibrils formed by the apolipoprotein A-I Leu174Ser variant: an atomic force microscopy study. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2004, 1690, 33-41.	1.8	19
358	Treatment of painful bone lesions and hypercalcemia. European Journal of Haematology, 1989, 43, 135-139.	1.1	19
359	Malnutrition at Diagnosis Predicts Mortality in Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. Journal of Parenteral and Enteral Nutrition, 2014, 38, 891-894.	1.3	19
360	Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis. Expert Opinion on Therapeutic Targets, 2017, 21, 1095-1110.	1.5	19

#	Article	IF	Citations
361	Validation of the Criteria of Response to Treatment In AL Amyloidosis.. Blood, 2010, 116, 1364-1364.	0.6	19
362	Neuropathies associated with monoclonal gammapathies. Haematologica, 1994, 79, 557-66.	1.7	19
363	Diagnostic approach to and follow-up of difficult cases of AL amyloidosis. Haematologica, 1995, 80, 409-15.	1.7	19
364	Complete remission in plasma cell leukaemia. British Journal of Haematology, 1986, 62, 525-527.	1.2	18
365	Structural and functional characterization of three human immunoglobulin Îº light chains with different pathological implications. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1996, 1317, 161-167.	1.8	18
366	Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1999, 6, 273-277.	1.4	18
367	Biological features of the clone involved in primary amyloidosis (AL). Leukemia, 2001, 15, 195-202.	3.3	18
368	The Pavia Approach to Clinical Protein Analysis. Clinical Chemistry and Laboratory Medicine, 2001, 39, 1025-8.	1.4	18
369	Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide. Clinica Chimica Acta, 2012, 413, 544-547.	0.5	18
370	Molecular Mechanisms of Amyloidosis. New England Journal of Medicine, 2003, 349, 1872-1873.	13.9	17
371	Heavy Chain Disease Can Be Detected by Capillary Zone Electrophoresis. Clinical Chemistry, 2005, 51, 247-249.	1.5	17
372	Mechanisms of Renal Damage in Plasma Cell Dyscrasias: An Overview. , 2006, 153, 66-86.		17
373	Development and preparation of a new serum protein reference material: feasibility studies and processing. Clinical Chemistry and Laboratory Medicine, 2010, 48, 805-813.	1.4	17
374	Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 64-66.	1.4	17
375	Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations. Clinica Chimica Acta, 2011, 412, 1262-1265.	0.5	17
376	Spinal cord stimulation markedly ameliorated refractory neuropathic pain in transthyretin Val30Met familial amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 87-90.	1.4	17
377	Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H1158-H1166.	1.5	17
378	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVIDâ€19 pandemic. British Journal of Haematology, 2020, 190, 346-357.	1.2	17

#	Article	IF	Citations
379	Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5ÂYears. Neurology and Therapy, 2020, 9, 105-115.	1.4	17
380	Insights into the regulation of immunoglobulin light chain gene rearrangements via analysis of the kappa light chain locus in lambda myeloma. Immunology, 2004, 112, 420-427.	2.0	16
381	Analysis of Hepatitis C Virus Hypervariable Region 1 Sequence from Cryoglobulinemic Patients and Associated Controls. Journal of Virology, 2007, 81, 4564-4571.	1.5	16
382	Risk stratification in WaldenstrÃ¶m macroglobulinemia. Expert Review of Hematology, 2012, 5, 187-199.	1.0	16
383	High^{99m}Tc-DPD myocardial uptake in a patient with apolipoprotein AI-related amyloidotic cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 48-51.	1.4	16
384	Early Identification of Transthyretin-Related HereditaryÂCardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2014, 7, 511-514.	2.3	16
385	Systemic amyloidoses and proteomics: The state of the art. EuPA Open Proteomics, 2016, 11, 4-10.	2.5	16
386	Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system. Journal of Neuroinflammation, 2017, 14, 115.	3.1	16
387	New concepts in the treatment and diagnosis of amyloidosis. Expert Review of Hematology, 2018, 11, 117-127.	1.0	16
388	Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. European Journal of Clinical Investigation, 2021, 51, e13598.	1.7	16
389	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	1.3	16
390	The relative amounts of plasma transthyretin forms in familial transthyretin amyloidosis: A quantitative analysis by Fourier transform ion-cyclotron resonance mass spectrometry. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 191-199.	1.4	15
391	Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome. Journal of Leukocyte Biology, 2016, 99, 761-769.	1.5	15
392	The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis. Clinical Chemistry and Laboratory Medicine, 2016, 54, 939-45.	1.4	15
393	Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy. Blood Cancer Journal, 2020, 10, 90.	2.8	15
394	Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study.. Journal of Clinical Oncology, 2021, 39, 8003-8003.	0.8	15
395	Procalcitonin Is Not a Reliable Marker for the Assessment of Severity in Acute Pancreatitis without Infectious Complications. Clinical Chemistry, 2000, 46, 428-430.	1.5	14
396	Pathogenesis of Renal Failure in Multiple Myeloma: Any Role of Contrast Media?. BioMed Research International, 2014, 2014, 1-10.	0.9	14

#	Article	IF	Citations
397	Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis. Clinical Chemistry and Laboratory Medicine, 2016, 54, 921-7.	1.4	14
398	Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurology and Therapy, 2021, 10, 753-766.	1.4	14
399	Age-related amyloidosis outside the brain: A state-of-the-art review. Ageing Research Reviews, 2021, 70, 101388.	5.0	14
400	Peptichemio induction therapy in myelomatosis. Cancer Chemotherapy and Pharmacology, 1982, 8, 9-16.	1.1	13
401	Clonality and specificity of cryoglobulins associated with HCV: pathophysiological implications. Journal of Hepatology, 1998, 29, 879-886.	1.8	13
402	Utility of biochemical markers in the follow-up of heart transplant recipients. Transplantation Proceedings, 2003, 35, 3075-3078.	0.3	13
403	The elusive pathogenesis of Schnitzler syndrome. Blood, 2018, 131, 944-946.	0.6	13
404	Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance. Leukemia, 2020, 34, 1187-1191.	3.3	13
405	Monoclonal autoimmunity in hematology. Haematologica, 1991, 76, 449-59.	1.7	13
406	Structural characterization of Îº II Inc, a new amyloid immunoglobulin. BBA - Proteins and Proteomics, 1989, 995, 103-108.	2.1	12
407	The second riboflavin-binding myeloma IgGÎ»DOT I. Biochemical and functional characterization. Molecular Immunology, 1990, 27, 385-394.	1.0	12
408	The putative role of alphaâ€1â€antitrypsin in the disaggregation of amyloid lambda fibrils. Journal of Internal Medicine, 1995, 237, 143-149.	2.7	12
409	Diagnostic Challenges of Amyloidosis in WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 244-246.	0.2	12
410	Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, S113-S118.	0.6	12
411	First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network. Blood, 2020, 136, 50-51.	0.6	12
412	MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study. Blood, 2012, 120, 731-731.	0.6	12
413	How we treat WaldenstrÃ¶m's macroglobulinemia. Haematologica, 2005, 90, 117-25.	1.7	12
414	Differential transplacental binding of valproic acid: influence of free fatty acids.. British Journal of Clinical Pharmacology, 1984, 17, 759-762.	1.1	11

#	Article	IF	Citations
415	Serum Thymidine Kinase and Beta-2 Microglobulin in Monoclonal Gammopathies. Tumori, 1987, 73, 445-449.	0.6	11
416	Mutation and transcription analysis of transthyretin gene in Italian families with hereditary amyloidosis: a putative novel â€˜hot spotâ€™ in codon 47. Clinical Genetics, 2001, 57, 284-290.	1.0	11
417	A Deiminated Viral Peptide to Detect Antibodies in Rheumatoid Arthritis. Annals of the New York Academy of Sciences, 2005, 1050, 243-249.	1.8	11
418	Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. Blood, 2020, 136, 48-50.	0.6	11
419	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. Blood, 2014, 124, 35-35.	0.6	11
420	Plasma cell DNA content in multiple myeloma and related paraproteinemic disorders. Relationship with clinical and cytokinetic features. European Journal of Cancer & Clinical Oncology, 1984, 20, 81-90.	0.9	10
421	Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma. European Journal of Cancer & Clinical Oncology, 1986, 22, 787-791.	0.9	10
422	Liver Transplantation: An Effective Treatment For Familial ATTR Amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 201-202.	1.4	10
423	Metrological sharp shooting for plasma proteins and peptides: The need for reference materials for accurate measurements in clinical proteomics and in vitro diagnostics to generate reliable results. Proteomics - Clinical Applications, 2007, 1, 1016-1035.	0.8	10
424	Serum-free light chain analysis: works in progress. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1021-2.	1.4	10
425	Beta2-microglobulin causes abnormal phosphatidylserine exposure in human red blood cells. Molecular BioSystems, 2011, 7, 651-658.	2.9	10
426	Expanding the spectrum of systemic amyloid diseases: aÂnew hint from the kidney. Kidney International, 2016, 90, 479-481.	2.6	10
427	Evidence that amyloidogenic light chains undergo antigen-driven selection. Blood, 1998, 91, 2948-54.	0.6	10
428	Treatment of AL amyloidosis with 4'-Iodo-4'-deoxydoxorubicin: an update. Blood, 1999, 93, 1112-3.	0.6	10
429	An N-glycosylation hotspot in immunoglobulin Îº light chains is associated with AL amyloidosis. Leukemia, 2022, 36, 2076-2085.	3.3	10
430	Use of an Anti-Idiotypic Monoclonal Antibody in Studying Amyloidogenic Light Chains in Cells, Urine and Fibrils: Pathophysiology and Clinical Implications. Scandinavian Journal of Immunology, 1992, 36, 607-616.	1.3	9
431	Pharmacokinetics of peptichemio in myeloma patients: release ofm-l-sarcolysin in vivo and in vitro. Cancer Chemotherapy and Pharmacology, 1993, 31, 265-268.	1.1	9
432	Immune mechanisms of AL amyloidosis. Drug Discovery Today Disease Mechanisms, 2004, 1, 365-373.	0.8	9

#	Article	IF	Citations
433	Characterization for anti-cytoplasmic antibodies specificity by morphological and molecular techniques. Autoimmunity Highlights, 2012, 3, 79-85.	3.9	9
434	Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson fromC. elegans. Worm, 2014, 3, e965590.	1.0	9
435	Determining the significance of MGUS. Blood, 2014, 123, 305-307.	0.6	9
436	A patient with AL amyloidosis with negative free light chain results. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1035-7.	1.4	9
437	Prognostication of survival and progression to dialysis in AA amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 136-137.	1.4	9
438	Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 56-57.	1.4	9
439	The Clinical Impact of Proteomics in Amyloid Typing. Mayo Clinic Proceedings, 2021, 96, 1122-1127.	1.4	9
440	Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome. Blood, 2018, 132, 2026-2026.	0.6	9
441	Late-Onset Familial Mediterranean Fever: An Atypical Presentation of Dermatologic Interest. Archives of Dermatology, 2007, 143, 1073.	1.7	8
442	Proteomics in protein misfolding diseases. Clinical Chemistry and Laboratory Medicine, 2009, 47, 627-35.	1.4	8
443	Introducing the New Editor ofAmyloid: the Journal of Protein Folding Disorders, Per Westermark, M.D., Ph.D.. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2010, 17, 99-100.	1.4	8
444	Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 11-13.	1.4	8
445	Enlightening light chain deposition disease. Blood, 2015, 126, 2770-2771.	0.6	8
446	A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options. BMC Medical Genetics, 2019, 20, 23.	2.1	8
447	Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS. Cardiology and Therapy, 2021, 10, 481-490.	1.1	8
448	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2022, 28, e1-e4.	0.7	8
449	Phase I/II study of bortezomib (B) in patients with systemic AL-amyloidosis (AL). Journal of Clinical Oncology, 2007, 25, 8050-8050.	0.8	8
450	An IgM monoclonal protein with multiple serological specificities. Clinical and Experimental Immunology, 1979, 37, 276-82.	1.1	8

#	Article	IF	Citations
451	Rate of M-component changes and plasma cell labeling index in 25 patients with multiple myeloma treated with peptichemio. Cancer Treatment Reports, 1985, 69, 971-5.	0.5	8
452	A PROSPECTIVE, CONTROLLED, NONRANDOMIZED STUDY ON PROPHYLACTIC PARENTERAL DICHLOROMETHYLENE BISPHOSPHONATE (CLODRONATE) IN MULTIPLE-MYELOMA. International Journal of Oncology, 1994, 5, 833-9.	1.4	7
453	Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition. Nephrology Dialysis Transplantation, 1996, 11, 1708-1711.	0.4	7
454	Autologous Stem Cell and Kidney Transplantation for Primary Amyloidosis Associated with ESRD: Which Should Come First?. American Journal of Transplantation, 2005, 5, 1585-1586.	2.6	7
455	A plea to overcome the concept of â€œstagingâ€•and related inadequacy in multiple myeloma. European Journal of Haematology, 1991, 46, 177-181.	1.1	7
456	Treating advanced cardiac damage in light chain amyloidosis: still an unmet need. Haematologica, 2014, 99, 1407-1409.	1.7	7
457	Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. Haematologica, 2017, 102, e411-e414.	1.7	7
458	A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis. Leukemia and Lymphoma, 2022, 63, 205-211.	0.6	7
459	Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.. Blood, 2008, 112, 1689-1689.	0.6	7
460	Ixazomib-dexamethasone (Ixa-Dex) vs physicianâ€™s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.. Journal of Clinical Oncology, 2020, 38, 8546-8546.	0.8	7
461	Population Pharmacokinetics and Exposureâ€Response Modeling of Daratumumab Subcutaneous Administration in Patients With Lightâ€Chain Amyloidosis. Journal of Clinical Pharmacology, 2022, 62, 656-669.	1.0	7
462	Amino acid sequence of the FV region of a human monoclonal IgM (NOV) with specificity for the capsular polysaccharide of the group B meningococcus and of Escherichia coli K1, which cross-reacts with polynucleotides and with denatured DNA. Journal of Immunology, 1991, 147, 915-20.	0.4	7
463	Hepatitis B virus markers in monoclonal (type I and II) and polyclonal (type III) cryoglobulinemias. Haematologica, 1988, 73, 375-8.	1.7	7
464	Reduced taste perception in AL amyloidosis. A frequently unnoticed sensory impairment. Haematologica, 1996, 81, 110-5.	1.7	7
465	Systemic amyloidosis: are we moving ahead?. Netherlands Journal of Medicine, 2004, 62, 104-5.	0.6	7
466	Primary (AL) Amyloidosis. Renal Failure, 1993, 15, 429-433.	0.8	6
467	Transthyretin, nutrition, and inflammation: response to Dr. Bernstein. Clinical Chemistry and Laboratory Medicine, 2007, 45, .	1.4	6
468	Molecular imaging of misfolded protein pathology for early clues to involvement of the heart. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1649-1651.	3.3	6

#	Article	IF	Citations
469	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e59-e60.	0.2	6
470	Etiology of Amyloidosis Determines Myocardial 99mTc-DPD Uptake in Amyloidotic Cardiomyopathy. Clinical Nuclear Medicine, 2015, 40, 446-447.	0.7	6
471	Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 68-69.	1.4	6
472	Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 64-65.	1.4	6
473	Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing. Proteomics, 2018, 18, e1700353.	1.3	6
474	Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 168-173.	1.4	6
475	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndromeâ€"Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. Frontiers in Medicine, 2021, 8, 668173.	1.2	6
476	Characterization of the Two Unique Human Anti-Flavin Monoclonal Immunoglobulins. FEBS Journal, 1995, 228, 886-893.	0.2	6
477	Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis. Blood, 2008, 112, 869-869.	0.6	6
478	Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. Blood, 2021, 138, 153-153.	0.6	6
479	Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network. Blood, 2021, 138, 2730-2730.	0.6	6
480	Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients. Clinical Chemistry and Laboratory Medicine, 2022, 60, 386-393.	1.4	6
481	Multiple myeloma and related plasma cell dyscrasias. JAMA - Journal of the American Medical Association, 1987, 258, 2930-7.	3.8	6
482	Familial AL-amyloidosis in three Italian siblings. Haematologica, 1996, 81, 105-9.	1.7	6
483	Procalcitonin is not a reliable marker for the assessment of severity in acute pancreatitis without infectious complications. Clinical Chemistry, 2000, 46, 428-30.	1.5	6
484	Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009038.	1.6	6
485	Calcium antagonists and hormone release. IV. The role of calcium in glucose-stimulated early phase insulin release in vivo. Journal of Endocrinological Investigation, 1982, 5, 121-124.	1.8	5
486	Peptichemio, Vincristine, Prednisone Induction Treatment in Multiple Myeloma. Tumori, 1985, 71, 581-588.	0.6	5

#	Article	IF	Citations
487	Selective bone marrow involvement of lymphoplasmacytic cells secreting monoclonal IgA rheumatoid factor in a patient with Sjogren's syndrome and serum hyperviscosity.. Annals of the Rheumatic Diseases, 1987, 46, 938-942.	0.5	5
488	Clinical, radiological, and biochemical features of a bilateral buttock amyloidoma emerging after 27 years of hemodialysis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 115-121.	1.4	5
489	The Merlini, WaldenstrÃ¶m, Jayakar staging system revisited. European Journal of Haematology, 1989, 43, 105-110.	1.1	5
490	Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 61-63.	1.4	5
491	What is a good journal?. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 91-91.	1.4	5
492	Serum Markers of Myocardial Damage in Acute Pancreatitis. Pancreas, 2015, 44, 678-680.	0.5	5
493	What does minimal residual disease mean in AL amyloidosis?. Expert Opinion on Orphan Drugs, 2018, 6, 703-705.	0.5	5
494	Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients. Blood, 2019, 134, 320-323.	0.6	5
495	Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice. Kidney International, 2019, 95, 258-260.	2.6	5
496	Access to Affordable Orphan Medicines in Europe: An EHA Position Paper. HemaSphere, 2020, 4, e477.	1.2	5
497	Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside. Expert Review of Hematology, 2020, 13, 1003-1015.	1.0	5
498	Clinical Amyloid Typing by Proteomics: Performance Evaluation and Data Sharing between Two Centres. Molecules, 2021, 26, 1913.	1.7	5
499	Search for AL amyloidosis risk factors using Mendelian randomization. Blood Advances, 2021, 5, 2725-2731.	2.5	5
500	Imaging of Systemic Amyloidosis. , 2010, , 15-32.		5
501	Outcomes By Cardiac Stage in Newly Diagnosed AL Amyloidosis: Results from Andromeda. Blood, 2020, 136, 44-45.	0.6	5
502	Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda. Blood, 2020, 136, 6-7.	0.6	5
503	A Phase II Trial of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) in Previously Treated Patients with AL Amyloidosis.. Blood, 2009, 114, 2863-2863.	0.6	5
504	Treatment of AL Amyloidosis with Bortezomib Combined with Alkylating Agents: Results From a Prospective Series of Unselected Patients,. Blood, 2011, 118, 3977-3977.	0.6	5

#	Article	IF	Citations
505	European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease. Blood, 2011, 118, 995-995.	0.6	5
506	Use of the Novel Monoclonal Assay for the Measurement of Circulating Free Light Chain in the Diagnosis, Prognostication of Survival and Assessment of Response to Therapy in AL Amyloidosis. Blood, 2012, 120, 3913-3913.	0.6	5
507	Treatment of AL Amyloidosis with Bendamustine. Blood, 2012, 120, 4057-4057.	0.6	5
508	Accurate Risk Stratification Identifies Patients with AL Amyloidosis Benefiting Most from Upfront Bortezomib Combinations: A Study of Treatment Outcomes in 984 Patients. Blood, 2015, 126, 190-190.	0.6	5
509	The VITAL Amyloidosis Study: A Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study of NEOD001 in Patients with AL Amyloidosis and Cardiac Dysfunction. Blood, 2016, 128, 5690-5690.	0.6	5
510	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. Blood, 2021, 138, 2721-2721.	0.6	5
511	Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study. Blood, 2021, 138, 159-159.	0.6	5
512	The laboratory investigation of monoclonal components. Haematologica, 1988, 73, 79-85.	1.7	5
513	Proliferative activity, response to therapy and survival in multiple myeloma. Haematologica, 1984, 69, 148-62.	1.7	5
514	Vincristine in the treatment of multiple myeloma. Haematologica, 1980, 65, 595-611.	1.7	5
515	Electrophoresis: cellulose acetate vs agarose gel, visual inspection vs densitometry. Clinical Chemistry, 1981, 27, 1944-5.	1.5	5
516	Monoclonal gammapathies. Journal of the International Federation of Clinical Chemistry, 1997, 9, 171-6.	0.1	5
517	Doxorubicin and congo red effectiveness on prion infectivity in golden Syrian hamster. Anticancer Research, 2009, 29, 2507-12.	0.5	5
518	Utility of bisphosphonates in treating bone metastases. Medical Oncology, 1996, 13, 215-221.	1.2	4
519	Conformational dynamics of the Î²2-microglobulin C terminal in the cell-membrane-anchored major histocompatibility complex type I. Cellular and Molecular Life Sciences, 2000, 57, 675-683.	2.4	4
520	Comparison of three strategies for myocardial protection during coronary artery bypass graft surgery based on markers of cardiac damage. Clinical Biochemistry, 2005, 38, 504-508.	0.8	4
521	Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 96-97.	1.4	4
522	Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A caseâ€“control study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 187-193.	1.4	4

#	Article	IF	Citations
523	Protein electrophoresis and serum free light chains in the diagnosis and monitoring of plasma cell disorders: laboratory testing and current controversies. Clinical Chemistry and Laboratory Medicine, 2016, 54, 899-905.	1.4	4
524	Advances in proteomic study of cardiac amyloidosis: progress and potential. Expert Review of Proteomics, 2016, 13, 1017-1027.	1.3	4
525	Regulated expression of amyloidogenic immunoglobulin light chains in mice. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 52-53.	1.4	4
526	How do we improve treatments for patients with amyloidosis using proteomics?. Expert Review of Proteomics, 2017, 14, 561-563.	1.3	4
527	Cardiac light-chain deposition disease relapsing in the transplanted heart. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 135-137.	1.4	4
528	Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 105-106.	1.4	4
529	A Prospective Phase II of Daratumumab in Previously Treated Systemic Light-Chain (AL) Amyloidosis: Updated Results. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e40-e41.	0.2	4
530	Future Perspectives. Hematology/Oncology Clinics of North America, 2020, 34, 1205-1214.	0.9	4
531	In search of the most effective therapy for light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 67-68.	1.4	4
532	OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis. Blood, 2019, 134, 3163-3163.	0.6	4
533	Hematologic Responses in Patients with Heavily Pretreated Light Chain Deposition Disease (LCDD) Receiving Daratumumab. Blood, 2018, 132, 1985-1985.	0.6	4
534	Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. Blood, 2021, 138, 2720-2720.	0.6	4
535	Alpha heavy chain disease: report of two cases. Haematologica, 1985, 70, 431-6.	1.7	4
536	Detection and identification of monoclonal components: immunoelectrophoresis on agarose gel and immunofixation on cellulose acetate compared. Clinical Chemistry, 1981, 27, 1862-5.	1.5	4
537	Nodular macroglossia with combined light chain and beta-2 microglobulin deposition in a long-term dialysis patient. Journal of Nephrology, 2001, 14, 128-31.	0.9	4
538	Waldenstrom's Macrogloblinemia/ Lymphoplasmacytic Lymphoma. , 2008, 142, 211-242.		4
539	Micropolyspora faeni antigens of three commercial extracts. Mycopathologia, 1984, 84, 165-169.	1.3	3
540	Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition. Nephrology Dialysis Transplantation, 1996, 11, 1708-1711.	0.4	3

#	Article	IF	Citations
541	Cholesterol control in stroke prevention in Italy: a cross-sectional study in family practice. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 159-163.	3.1	3
542	Embryonic stem and haematopoietic progenitor cells resist to AÎ² oligomer toxicity and maintain the differentiation potency in culture. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2010, 17, 137-145.	1.4	3
543	Patient Experience With Light Chain Amyloidosis: A Survey From the Amyloidosis Research Consortium. Journal of Cardiac Failure, 2015, 21, S63.	0.7	3
544	Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 66-67.	1.4	3
545	Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 54-55.	1.4	3
546	SAFETY OF INOTERSEN TREATMENT IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY. Journal of the American College of Cardiology, 2019, 73, 909.	1.2	3
547	Proteomics Fundamentally Advance the Diagnosis and Management of Amyloidosis. Mayo Clinic Proceedings, 2020, 95, 1816-1818.	1.4	3
548	Perspectives in developments of mass spectrometry for improving diagnosis and monitoring of multiple myeloma and other plasma cell disorders. Clinical Chemistry and Laboratory Medicine, 2021, 59, 633-635.	1.4	3
549	Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis. Current Clinical Pathology, 2015, , 9-29.	0.0	3
550	Treatment with Oral Melphalan and Dexamethasone of An Extended Patient Population with AL Amyloidosis.. Blood, 2009, 114, 3889-3889.	0.6	3
551	FISH reveals chromosomal abnormalities in 41 Patients with Systemic Amyloidosis (AL).. Blood, 2010, 116, 1197-1197.	0.6	3
552	Assessing Proteostasis and Proteasome Stress In Light Chain Amyloidosis. Blood, 2010, 116, 3992-3992.	0.6	3
553	Primary Therapy of Waldenstroì`m's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network. Blood, 2010, 116, 1941-1941.	0.6	3
554	Efficacy of peptide bound m-l-sarcolysin (peptichemio) on melphalan resistant human myeloma cellsIn vitro. Medical Oncology and Tumor Pharmacotherapy, 1991, 8, 265-269.	1.0	3
555	Gene expression of pyrogenic cytokines in Hodgkin's disease lymph nodes. Haematologica, 1992, 77, 221-5.	1.7	3
556	Severity in biliary peritonitis. Giornale Di Chirurgia, 2012, 33, 168-71.	0.5	3
557	Healthâ€related quality of life in patients with <scp>light chain</scp> amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasoneâ€‰Â±â€‰daratumumab: Results from the <scp>ANDROMEDA</scp> study. American Journal of Hematology, 2022, 97, 719-730.	2.0	3
558	Two-hit strategy for treating AL amyloidosis?. Blood, 2021, 138, 2596-2598.	0.6	3

#	Article	IF	Citations
559	Multivariate statistical analysis of quantitative serum protein data in populations of Rwanda. American Journal of Physical Anthropology, 1981, 55, 13-20.	2.1	2
560	Serum Alpha-1-Acid-Glycoprotein, Haptoglobin and C₃ in Hodgkinâ€™s Disease. Acta Haematologica, 1982, 67, 255-262.	0.7	2
561	Functional study of autonomic neuropathy in primary (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1996, 3, 167-172.	1.4	2
562	Refining therapy for AL amyloidosis. Blood, 2006, 108, 3632-3633.	0.6	2
563	Obstructive intramural coronary amyloidosis: a distinct phenotype of cardiac amyloidosis that can cause acute heart failure. European Heart Journal, 2006, 27, 1810-1810.	1.0	2
564	Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins. Molecular Immunology, 2008, 45, 1519-1524.	1.0	2
565	A focus on recent advances in proteomics â€“ one step closer to entrance into the clinical arena. Clinical Chemistry and Laboratory Medicine, 2009, 47, 625-6.	1.4	2
566	Can ISSWM Be Used for Making Treatment Decisions?. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 121-123.	0.2	2
567	Reducing the amyloid burden through immunotherapy: a major therapeutic advance. Nephrology Dialysis Transplantation, 2011, 26, 1471-1473.	0.4	2
568	Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. Annals of Hematology, 2013, 92, 1133-1134.	0.8	2
569	Recommendations for appropriate serum electrophoresis requests: the Italian approach. Clinical Chemistry and Laboratory Medicine, 2013, 51, e117-e118.	1.4	2
570	Hereditary apolipoprotein A1 amyloidosis with cutaneous and cardiac involvement: a long familial history. European Journal of Dermatology, 2014, 24, 261-263.	0.3	2
571	Patterns of relapse after upfront bortezomib therapy in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 60-61.	1.4	2
572	Persistence of Minimal Residual Disease by Multiparameter Flow Cytometry Can Hinder Recovery of Organ Damage in Patients With AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e24.	0.2	2
573	WaldenstrÃ¶mâ€™s Macroglobulinemia. Hematologic Malignancies, 2018, , 191-220.	0.2	2
574	Seek and You Shall Find: Is Subclinical Amyloid More Common Than Expected?. Mayo Clinic Proceedings, 2018, 93, 1546-1548.	1.4	2
575	The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 107-108.	1.4	2
576	Here to Stay: Biosimilars in Hematology. HemaSphere, 2019, 3, e323.	1.2	2

#	Article	IF	Citations
577	Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 209-210.	0.8	2
578	Amyloid Typing: Immunoelectron Microscopy. , 2012, , 249-260.		2
579	Cholesterol control in stroke prevention in Italy: a cross-sectional study in family practice. European Journal of Cardiovascular Prevention and Rehabilitation, 2005, 12, 159-163.	3.1	2
580	Long-Term Update from the Open-Label Extension of the NEURO-TTR Study in Patients with Hereditary Transthyretin Amyloidosis. Blood, 2018, 132, 498-498.	0.6	2
581	The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy. Blood, 2019, 134, 1901-1901.	0.6	2
582	First Line Therapy With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) In Patients With AL Amyloidosis and Potentially Reversible Contraindications To Autologous Stem Cell Transplant. Blood, 2013, 122, 1985-1985.	0.6	2
583	High-Dose Pomalidomide and Dexamethasone Induce Rapid Responses In Patients With AL Amyloidosis Exposed To Alkylators, Immune Modulatory Drugs, and Proteasome Inhibitors. Blood, 2013, 122, 288-288.	0.6	2
584	Patients with AL Amyloidosis and Low Free Light Chain Burden Have Distinct Clinical Features and Outcome. Blood, 2015, 126, 1773-1773.	0.6	2
585	Patterns of Relapse after Upfront Therapy in AL Amyloidosis. Blood, 2016, 128, 2140-2140.	0.6	2
586	Transthyretin-associated Familial Amyloid Polyneuropathy - Current and Emerging Therapies. European Neurological Review, 2012, 7, 14.	0.5	2
587	Pilot Study with Lenalidomide in Patients with POEMS Syndrome. Blood, 2011, 118, 4612-4612.	0.6	2
588	The PRONTO amyloidosis study: A randomized, double-blind, placebo-controlled, global, phase 2b study of NEOD001 in previously treated subjects with light chain amyloidosis and persistent cardiac dysfunction.. Journal of Clinical Oncology, 2016, 34, TPS8073-TPS8073.	0.8	2
589	Outcomes of Patients with t(11;14) Multiple Myeloma: An International Myeloma Working Group Multicenter Study. Blood, 2019, 134, 3066-3066.	0.6	2
590	Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis. Blood, 2019, 134, 1860-1860.	0.6	2
591	OAB-034: Evaluating the impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis: subanalyses from the ANDROMEDA study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S22.	0.2	2
592	Immunochemical characteristics of a particular cryoglobulin. A new cryoglobulin subgroup?. Clinical and Experimental Rheumatology, 1991, 9, 399-402.	0.4	2
593	Peptichemio, vincristine, prednisone induction treatment in multiple myeloma. Tumori, 1985, 71, 581-8.	0.6	2
594	More on immunofixation vs immunoelectrophoresis. Clinical Chemistry, 1984, 30, 1113.	1.5	2

#	Article	IF	Citations
595	Uniform risk-stratification and response criteria are paving the way to evidence-based treatment of AL amyloidosis. Oncology, 2011, 25, 633, 637-8.	0.4	2
596	Treatment of Multiple Myeloma with Vincristine. Acta Haematologica, 1980, 64, 176-178.	0.7	1
597	Application of Monoclonal Anti-idiotypes in the Study of AL Amyloidosis: Therapeutic Implications. Renal Failure, 1993, 15, 365-371.	0.8	1
598	Perturbations of the Kepler Problem in Global Coordinates: A Program. Celestial Mechanics and Dynamical Astronomy, 2001, 81, 313-319.	0.5	1
599	Sharpening therapeutic strategy in AL amyloidosis. Blood, 2004, 104, 1593-1594.	0.6	1
600	Systemic Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1912-1915.	2.2	1
601	Amyloidosis presenting with Fabry disease. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 231-232.	1.4	1
602	An ECG/ECHO comparison between AL and ATTR cardiac amyloidosis at diagnosis. European Heart Journal, 2013, 34, P2991-P2991.	1.0	1
603	Reply to S. Girnius et al. Journal of Clinical Oncology, 2013, 31, 2750-2751.	0.8	1
604	THU0376â€...Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Annals of the Rheumatic Diseases, 2013, 71, 282.3-283.	0.5	1
605	PP100-SUN: Nutritional Counseling in Systemic Immunoglobulin Light-Chain (AL) Amyloidosis: A Prospective Randomized, Controlled Trial. Clinical Nutrition, 2014, 33, S56-S57.	2.3	1
606	Protein aggregation. International Journal of Biological Macromolecules, 2017, 100, 1-2.	3.6	1
607	Kidney Involvement in Light Chain Amyloidosis. Journal of Onco-Nephrology, 2017, 1, 110-119.	0.3	1
608	Inotersen Improves Quality of Life and Neuropathy in Patients with Hereditary Transthyretin (HATTR) Amyloidosis with Polyneuropathy: Results of the Phase 3 Study Neuro-TTR. Value in Health, 2018, 21, S202.	0.1	1
609	Efficacy and Safety of Tafamidis Doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). Journal of Cardiac Failure, 2019, 25, S77-S78.	0.7	1
610	PS1221ÂLONGâ€¶TERM EFFICACY AND SAFETY OF INOTERSEN FOR HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: NEUROâ€¶TTR OPENâ€ŁABEL EXTENSION 2â€¶YEAR UPDATE. HemaSphere, 2019, 3, 557.	1.2	1
611	PS1349 UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA. HemaSphere, 2019, 3, 616.	1.2	1
612	High sensitivity Mâ€protein detection in a case of lightâ€chain cardiac amyloidosis without evidence of plasma cell dyscrasia. American Journal of Hematology, 2019, 94, 619-621.	2.0	1

#	Article	IF	Citations
613	A powerful oral triplet for AL amyloidosis. British Journal of Haematology, 2020, 189, 605-606.	1.2	1
614	Impact of Inotersen on Subgroups of Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial. Blood, 2018, 132, 4803-4803.	0.6	1
615	Impact of Inotersen on Functioning and Activities of Daily Living for Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial. Blood, 2018, 132, 4812-4812.	0.6	1
616	Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenstrÃ¶M's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years. Blood, 2016, 128, 2957-2957.	0.6	1
617	Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis. Blood, 2016, 128, 648-648.	0.6	1
618	Weekly and twice-weekly bortezomib in AL amyloidosis: Results of a phase II study.. Journal of Clinical Oncology, 2010, 28, 8023-8023.	0.8	1
619	MYOCARDIAL SYSTOLIC DYSFUNCTION IN CARDIAC AL AMYLOIDOSIS WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION. Journal of Hypertension, 2004, 22, S174-S175.	0.3	1
620	A Proteomic Approach to the Study of Systemic Amyloidoses. , 2007, , 360-362.		1
621	Clinical Trial for Ttr Amyloidosis Using Diflunisal. , 2007, , 387-389.		1
622	Treatment and Outcome of 267 Patients with IgM-Related AL Amyloidosis. Blood, 2012, 120, 4074-4074.	0.6	1
623	Identification Of Reversible Organ Damage and Of Early Markers Of Response To Treatment In Renal AL Amyloidosis: A Study On 461 Patients. Blood, 2013, 122, 3087-3087.	0.6	1
624	Abstract 2693: Mass spectrometric approach to identify N-glycosylation of light chain in patients with immunoglobulin light chain amyloidosis (AL). Cancer Research, 2018, 78, 2693-2693.	0.4	1
625	Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN). Blood, 2019, 134, 1868-1868.	0.6	1
626	Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis. Blood, 2019, 134, 3312-3312.	0.6	1
627	A sulfhydryl-rich IgM protein with multiple serological specificities. Clinical and Experimental Immunology, 1987, 69, 148-56.	1.1	1
628	The Italian Medicines Agency Prospective Registry of Bortezomib-Based Treatment in AL Amyloidosis. Blood, 2020, 136, 22-22.	0.6	1
629	Future Developments in Light Chain Amyloidosis Management. American Journal of Medicine, 2022, 135, S53-S57.	0.6	1
630	Alpha-2-HS-glycoprotein in multiple myeloma. Haematologica, 1982, 67, 845-52.	1.7	1

#	Article	IF	Citations
631	Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition. Nephrology Dialysis Transplantation, 1996, 11, 1708-11.	0.4	1
632	Measurement of free light chains in urine. Clinical Chemistry, 2001, 47, 2069-70.	1.5	1
633	A simple electrophoretic procedure for isoamylase separation. Research in Clinic and Laboratory, 1984, 14, 443-447.	0.3	1
634	Clinical usefulness of the molecular interpretation of the cellulose acetate serum protein electrophoresis. Research in Clinic and Laboratory, 1980, 10, 239-242.	0.3	0
635	Identification of Specific Plasma Proteins Determining the Agarose Gel Electrophoresis by the Immunosubtraction Technique. Clinical Chemistry and Laboratory Medicine, 1983, 21, 841-4.	1.4	0
636	A Case of IgM(Â) Monoclonal Gammopathy Simulating an IgM-IgG Biclonal Gammopathy. Annals of Clinical Biochemistry, 1990, 27, 158-160.	0.8	0
637	Characterization of the Two Unique Human Anti-Flavin Monoclonal Immunoglobulins. FEBS Journal, 1995, 228, 886-893.	0.2	0
638	Pavia, Italy Symposium. Recent Developments in Amyloidosis, June 1, 1995. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1996, 3, 57-58.	1.4	0
639	Symposium on Amyloid Cardiomyopathy: Diagnosis and Treatment, Pavia, September 21, 1996. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1997, 4, 296-299.	1.4	0
640	407 Mutations at position 385 within the hypervariable region 1 (HVR1) of the hepatitis C virus (HCV) are rare and not restricted to patients with cryoglobulinemia. Journal of Hepatology, 2004, 40, 121.	1.8	0
641	Pharmacokinetic Study Of Rituximab In Hematologic Malignancies And Autoimmune Disorders. Therapeutic Drug Monitoring, 2005, 27, 241.	1.0	0
642	Exciting new agents in multiple myeloma. Blood, 2006, 108, 3235-3236.	0.6	0
643	WALDENSTRÃ–M MACROGLOBULINEMIA/LYMPHOPLASMACYTIC LYMPHOMA. , 0, , 129-149.		0
644	Monoclonal gammopathies. BMC Geriatrics, 2010, 10, .	1.1	0
645	AMICA: an electronic patient record specifically designed for an amyloidosis network. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 236-238.	1.4	0
646	A workflow management system for the biological samples exchange within the amyloidosis network. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 233-235.	1.4	0
647	Late onset cardiomyopathy due to transthyretin Ile68Leu mutation: a cardiogenic variant of familial amyloidosis potentially mimicking sarcomeric hypertrophic cardiomyopathy. European Heart Journal, 2013, 34, P2958-P2958.	1.0	0
648	The role of gender and age in cardiac AL amyloidosis. European Heart Journal, 2013, 34, P2996-P2996.	1.0	0

#	Article	IF	Citations
649	Is a restrictive LV filling pattern invariably present in restrictive cardiomyopathy? The case of cardiac AL amyloidosis. European Heart Journal, 2013, 34, P2442-P2442.	1.0	0
650	Amyloidogenic light chains induce human cardiac fibroblast toxicity through alteration of mitochondrial functionality. European Heart Journal, 2013, 34, P4239-P4239.	1.0	0
651	Waldenstromâ€™s macroglobulinemia/lymphoplasmacytic lymphoma. , 0, , 190-215.		0
652	WaldenstrÃ¶m's macroglobulinemia/lymphoplasmacytic lymphoma. , 0, , 138-154.		0
653	A simple model to predict survival using age, comorbidities and functional status in patients with multiple myeloma (MM). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e94-e95.	0.2	0
654	[PP.33.16] IN RESTRICTIVE CARDIOMYOPATHY CAUSED BY CARDIAC AL AMYLOIDOSIS A RESTRICTIVE LV FILLING PATTERN IS ONLY PRESENT IN A MINORITY OF PATIENTS. Journal of Hypertension, 2016, 34, e328.	0.3	0
655	Growth Differentiation Factor 15 (GDF-15) Is a New Biomarker for Overall Survival and Renal Outcomes in Patients with Light Chain (AL) Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e40.	0.2	0
656	Unusual Manifestations of IgM Monoclonal Gammopathies. , 2017, , 223-236.		0
657	Primary Systemic Amyloidosis. Hematologic Malignancies, 2018, , 221-245.	0.2	0
658	Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial: Sensitivity Analyses Further Support the Primary Results. Journal of Cardiac Failure, 2018, 24, 813.	0.7	0
659	A revised international prognostic score system for WaldenstrÃ¶mâ€™s macroglobulinemia. Annals of Oncology, 2018, 29, viii359.	0.6	0
660	WaldenstrÃ¶m Macroglobulinemia/Lymphoplasmacytic Lymphoma. , 2018, , 1419-1431.e5.		0
661	Waldenstromâ€™s Macroglobulinemia. , 2018, , 617-638.		0
662	Analysis of NT-proBNP Baseline Levels in APOLLO as a Predictor of Survival in Hereditary Transthyretin-mediated (hATTR) Amyloidosis. Archives of Cardiovascular Diseases Supplements, 2019, 11, e322.	0.0	0
663	New Insights Into a Multifaceted Disease. Mayo Clinic Proceedings, 2019, 94, 388-390.	1.4	0
664	EFFECTS OF PATISIRAN, AN RNA INTERFERENCE THERAPEUTIC, ON REGIONAL LEFT VENTRICULAR MYOCARDIAL DEFORMATION IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: THE APOLLO STUDY. Journal of the American College of Cardiology, 2019, 73, 816.	1.2	0
665	PF564 OUTCOMES OF PATIENTS WITH T(11;14) MULTIPLE MYELOMA: AN INTERNATIONAL MYELOMA WORKING GROUP MULTICENTER STUDY. HemaSphere, 2019, 3, 234-235.	1.2	0
666	Light Chains With Heavy Effects. American Journal of Kidney Diseases, 2020, 75, 291-293.	2.1	0

#	Article	IF	Citations
667	Redirecting proteoxicity. Leukemia, 2020, 34, 3109-3110.	3.3	0
668	Introduction. Hematology/Oncology Clinics of North America, 2020, 34, xv-xvi.	0.9	0
669	Be SMART About AL Amyloidosis. Mayo Clinic Proceedings, 2021, 96, 1390-1392.	1.4	0
670	P3491 Circulating N terminal pro-brain natriuretic peptide as a marker of cardiac dysfunction in AL amyloidosis. European Heart Journal, 2003, 24, 678.	1.0	0
671	AMYLOID-INDUCED MYOCARDIAL DYSFUNCTION DEPENDS ON THE BIOCHEMICAL CHARACTERISTICS OF THE AMYLOIDOGENIC PROTEIN AT COMPARABLE DEGRESS OF CARDIAC DEPOSITION. Journal of Hypertension, 2004, 22, S185.	0.3	0
672	Experience with a Patient-Adapted Approach to Autologous Peripheral Blood Stem Cell Transplantation in Al Amyloidosis. , 2004, , 109-111.		0
673	Thalidomide plus Intermediate-Dose Dexamethasone in Refractory/Relapsed Al Patients. , 2004, , 115-117.		0
674	Amyloid versus Non-Amyloid Immunoglobulin Deposits. , 2004, , 133-135.		0
675	Human Monoclonal Cryocrystalglobulinemia: First Complete Heavy and Light Chain Variable Region Nucleotide Sequences.. Blood, 2004, 104, 1381-1381.	0.6	0
676	Uncommon Conditions Underlying AA Amyloidosis. , 2004, , 521-523.		0
677	Beneficial Effects of Eprodisate (NC-503) for Patients with Amyloid A (AA) Amyloidosis. American Journal of Gastroenterology, 2006, 101, S455.	0.2	0
678	Early Harvest Followed by Melphalan-Dexamethasone and Second-Line Autologous Stem Cell Transplantation in AL Amyloidosis.. Blood, 2006, 108, 5449-5449.	0.6	0
679	Prognostic Relevance of Serum N-Terminal Pronatriuretic Peptide Type B and Plasma Bnp in Patients with Al Amyloidosis in Dialysis. , 2007, , 273-274.		0
680	Early Harvest Followed by Melphalan-Dexamethasone and second-Line Autologous Stem Cell Transplantation in Al. , 2007, , 390-392.		0
681	Keynote Address: Advances in Systemic Amyloidoses. , 2007, , 341-346.		0
682	Prolonged Follow-up Study of Al Patients Ineligible for Stem Cell Transplantation Treated with Oral Melphalan and Dexamethasone. , 2007, , 282-282.		0
683	High-Sensitivity Troponin Assay Improves the Detection of Cardiac Involvement in AL Amyloidosis and Is the Most Powerful Prognostic Determinant.. Blood, 2009, 114, 1782-1782.	0.6	0
684	Pathogenesis of Systemic Amyloidoses. , 2010, , 49-64.		0

#	Article	IF	Citations
685	Salvage Therapy with Lenalidomide and Dexamethasone (LDex) In Patients with Advanced AL Amyloidosis Refractory to Both Melphalan and Bortezomib. Blood, 2010, 116, 3062-3062.	0.6	0
686	Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis. , 2012, , 9-29.		0
687	WaldenstrÃ¶mâ€™s Macroglobulinemia/Lymphoplasmacytic Lymphoma. , 2013, , 83-109.		0
688	WaldenstrÃ¶mâ€™s Macroglobulinemia. , 2014, , 303-329.		0
689	Aprotinin 99mTc Myocardial Scan: Risk Stratification of Cardiac Events in Patients with Al/Attr Amyloidosis. , 1999, , 479-482.		0
690	A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with Systemic AL Amyloidosis. Blood, 2014, 124, 305-305.	0.6	0
691	Free Light Chain Burden and Elevated Alkaline Phosphatase Identify Patients with Non-Cardiac AL Amyloidosis with Poor Outcome. Blood, 2014, 124, 3361-3361.	0.6	0
692	The Role of Differential Proteomics in Amyloid Typing: The Experience of the Pavia Referral Center. Current Clinical Pathology, 2015, , 323-330.	0.0	0
693	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). Blood, 2015, 126, 3292-3292.	0.6	0
694	Pomalidomide and Dexamethasone Grant Rapid Hematologic Responses in Patients with Relapsed and Refractory AL Amyloidois: A European Retrospective Series of 150 Patients. Blood, 2018, 132, 3264-3264.	0.6	0
695	OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S23-S24.	0.2	0
696	Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial. Blood, 2021, 138, 4771-4771.	0.6	0
697	Single Molecule Real-Time Sequencing of the M Protein (SMaRT M-Seq): Toward Personalized Medicine Approaches in Monoclonal Gammopathies. Blood, 2021, 138, 2673-2673.	0.6	0
698	Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma. Blood, 2021, 138, 4725-4725.	0.6	0
699	Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey. Blood, 2020, 136, 11-11.	0.6	0
700	Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients. Blood, 2020, 136, 33-34.	0.6	0
701	Immunoenzymatic detection of proteins transferred on nitrocellulose after fixation and staining in polyacrylamide gel. Haematologica, 1988, 73, 321-3.	1.7	0
702	Characterization of anti-streptolysin O activity of a human monoclonal IgG lambda. Haematologica, 1987, 72, 233-6.	1.7	0

#	Article	IF	Citations
703	Familial myeloma. A new observation in two distinct pairs of siblings. Haematologica, 1985, 70, 324-8.	1.7	0
704	Rate of M-component changes and clinical course of 23 responsive myeloma patients. Haematologica, 1984, 69, 305-14.	1.7	0
705	Serum IgD in Hodgkin's disease. Haematologica, 1981, 66, 35-45.	1.7	0
706	Plasma proteins modifications in pre-term newborns. Haematologica, 1981, 66, 682-6.	1.7	0
707	Agarose gel electrophoresis in newborns. Haematologica, 1981, 66, 687-90.	1.7	0
708	Non-tropical idiopathic splenomegaly. Report of a case. Haematologica, 1982, 67, 255-60.	1.7	0
709	Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. , 0, , 207-227.		0
710	Immunoassay methods for determination of serum C-reactive protein levels. Research in Clinic and Laboratory, 1984, 14, 581-585.	0.3	0